Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;24(3):640-7.
doi: 10.1093/annonc/mds334. Epub 2012 Oct 3.

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

P Dubsky  1 , M Filipits, R Jakesz, M Rudas, C F Singer, R Greil, O Dietze, I Luisser, E Klug, R Sedivy, M Bachner, D Mayr, M Schmidt, M C Gehrmann, C Petry, K E Weber, R Kronenwett, J C Brase, M Gnant; Austrian Breast and Colorectal Cancer Study Group (ABCSG)
Affiliations

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

P Dubsky et al. Ann Oncol. 2013 Mar.

Abstract

Background: In early estrogen receptor (ER)-positive/HER2-negative breast cancer, the decision to administer chemotherapy is largely based on prognostic criteria. The combined molecular/clinical EndoPredict test (EPclin) has been validated to accurately assess prognosis in this population. In this study, the clinical relevance of EPclin in relation to well-established clinical guidelines is assessed.

Patients and methods: We assigned risk groups to 1702 ER-positive/HER2-negative postmenopausal women from two large phase III trials treated only with endocrine therapy. Prognosis was assigned according to National Comprehensive Cancer Center Network-, German S3-, St Gallen guidelines and the EPclin. Prognostic groups were compared using the Kaplan-Meier survival analysis.

Results: After 10 years, absolute risk reductions (ARR) between the high- and low-risk groups ranged from 6.9% to 11.2% if assigned according to guidelines. It was at 18.7% for EPclin. EPclin reassigned 58%-61% of women classified as high-/intermediate-risk (according to clinical guidelines) to low risk. Women reclassified to low risk showed a 5% rate of distant metastasis at 10 years.

Conclusion: The EPclin score is able to predict favorable prognosis in a majority of patients that clinical guidelines would assign to intermediate or high risk. EPclin may reduce the indications for chemotherapy in ER-positive postmenopausal women with a limited number of clinical risk factors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier plot of distant metastasis-free survival (MFS) by (A) German S3, (B) National Comprehensive Cancer Center Network (NCCN), (C) St Gallen guidelines and (D) EPclin risk groups. 95% confidence intervals (CI) of hazard ratios (HR) are indicated.
Figure 2
Figure 2
Kaplan–Meier plot of distant metastasis-free survival (MFS) by EPclin risk groups after considering the (A) German S3, (B) National Comprehensive Cancer Center Network (NCCN) and (C) St Gallen guidelines.
Figure 3
Figure 3
Kaplan–Meier plot of distant metastasis-free survival (MFS) by EPclin risk groups after considering the biological subtypes (A) ‘Luminal B’ and (B) ‘Luminal A’.
Figure 4
Figure 4
Kaplan–Meier plot of distant metastasis-free survival (MFS) by EPclin risk groups in (A) grade 1 tumors, (B) grade 2 tumors and (C) grade 3 tumors.
Figure 5
Figure 5
Putative risk classification scheme for estrogen receptor (ER)-positive, HER2-negative breast cancer patients by combining clinical guidelines and the EPclin test. Metastasis-free survival (MFS) rates are based on the 1702 ER-positive, HER2-negative breast cancer samples.
See this image and copyright information in PMC

References

    1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717. - PubMed
    1. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–1792. - PubMed
    1. Fisher B, Jeong JH, Bryant J, et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004;364:858–868. - PubMed
    1. Carlson RW, Brown E, Burstein HJ, et al. NCCN task force report: adjuvant therapy for breast cancer. J Natl Compr Cancer Netw. 2006;4(Suppl 1):S1–S26. - PubMed
    1. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes––dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22:1736–1747. - PMC - PubMed

MeSH terms